7
Feb
2024
Scion Starts with $310M to Build ‘Exceptional’ Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2024
Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2024
Sanofi Shells Out for Inhibrx, CG’s Breakout IPO, & a Cure for a Rare Deafness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2024
Gene Expression In Therapeutic R&D: Rick Young on The Long Run
Today’s guest on The Long Run is Richard A. Young. Rick is a professor of biology at MIT and a core member of the Whitehead Institute dating back to its founding in the 1980s. Rick’s long and prolific research career has been dedicated to studying gene expression. He’s won a number of awards, and is a member of the National... Read More
18
Jan
2024
Arena Debuts with a Bang, Vertex Extends CRISPR, & BridgeBio Builds War Chest
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jan
2024
GSK Buys TSLP Antibody, J&J’s ADC Play, & Merck Adds Harpoon T-Cell Engagers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jan
2024
Investing in Healthy Aging: Jens Eckstein on The Long Run
Jens Eckstein is today’s guest on The Long Run. He’s an investment partner at Hevolution Foundation. It’s a Saudi Arabia-backed fund that supports basic research in healthy aging and invests in startups with partners to translate that science into interventions that help people live healthier, longer lives. These efforts are sometimes branded as increasing “healthspan” if not necessarily “lifespan.” Jens... Read More
4
Jan
2024
Karuna and RayzeBio Acquired, TCGX’s $1B Crossover Bet, & Cytokinetics’ Breakout
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2024
MOMA Gets Roche Deal, $66M Upfront, to Discover Novel Small Molecule Cancer Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Dec
2023
Give to the Next Generation of Scientists
This is the time of year when many people sit down and think about the causes they want to support. I’m asking you to consider donating today to young scientists through the Damon Runyon Cancer Research Foundation. Why Young Scientists? Our system for funding science doesn’t do enough to support young people. The average age of a first-time NIH grant... Read More
26
Dec
2023
Bispecific Antibodies for Cancer: Shelley Force Aldred and Nathan Trinklein on The Long Run
Today, I have a dynamic duo of scientific entrepreneurs on the show – Shelley Force Aldred and Nathan Trinklein. They are the co-founders of San Francisco-based Rondo Therapeutics. The company raised $67 million in a Series A financing announced in March 2022. Shelley is the CEO and Nathan is the chief scientific officer. Rondo is developing bispecific T-cell engaging antibodies... Read More
14
Dec
2023
Pfizer Closes Seagen, a Historic CRISPR Approval, & FTC Takes Shot at Sanofi
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Dec
2023
The Small Molecule Drug Discovery Renaissance: Jeff Jonker on The Long Run
Today’s guest is on The Long Run is Jeff Jonker. He’s the CEO of San Diego-based Belharra Therapeutics. It’s a startup that came out of stealth mode in January 2023 with a $50 million Series A financing from Versant Ventures, and a partnership with Genentech. I wrote about it at the time on TimmermanReport.com and am providing a link for... Read More
7
Dec
2023
AbbVie Buys Cerevel, Roche Buys Carmot, & Crowley Steps Into the Lion’s Den
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Dec
2023
Third Rock Joins F-Prime, Omega in $90M Round for ARTBIO’s Targeted Radiotherapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2023
Join Me and a Terrific Lineup for ‘Bridging the Gap’ Jan. 23 in Cambridge, Mass.
I’m excited to announce “Bridging the Gap.” It’s an event for the biotech innovation community Jan. 23 in Cambridge, Mass. An outstanding group of speakers is coming together to support a new generation of scientists through the Damon Runyon Cancer Research Foundation. Time: Noon-7 pm Date: Jan. 23 Place: The Engine. 750 Main St., Cambridge, Mass. Tickets are limited. Buy... Read More
30
Nov
2023
ImmunoGen’s Payday, FDA Jolts CAR-T Field, & Another Dupixent Win
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2023
The Final Frontier of Brain Science: Nancy Stagliano on The Long Run
Today’s guest on The Long Run is Nancy Stagliano. She’s the CEO of South San Francisco-based Neuron23. The company is privately held and was started in late 2018. The idea, like we’ve seen in oncology, is to develop targeted therapies for molecularly-defined subgroups of patients with Parkinson’s, Alzheimer’s, and other common neurodegenerative diseases. Nancy is a neuroscientist by training. She... Read More
16
Nov
2023
UK Clears 1st CRISPR Drug, Lilly’s siRNA for CV Disease & Blackstone’s Anti-Clotting Win
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2023
Leading the Fight Against Infectious Disease: Diana Brainard on The Long Run
Today’s guest is Diana Brainard. She’s the CEO of Waltham, Mass.-based AlloVir. AlloVir is developing off-the-shelf T cell therapies to fight common viruses. The company is developing these T cells, from donors, and modifying them so they can be given to patients with weakened immune systems. The company’s lead T-cell therapy candidate is made to fight six common viruses, including... Read More